What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Amgen Inc.'s unaudited financial results for the first quarter ended March 31, 2026. It furnishes the company's earnings press release, which contains detailed financial information and analysis.

What are non-GAAP financial measures and why does Amgen use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) reporting. Amgen uses them, including non-GAAP earnings per share and operating income, to provide investors with additional insights into the company's ongoing business operations. They are intended to facilitate comparisons across periods by excluding items that may be volatile or not indicative of core performance, such as acquisition-related expenses and restructuring costs.

What types of expenses are excluded when calculating Amgen's non-GAAP results?

Amgen excludes several types of expenses from its non-GAAP calculations. These include acquisition-related charges (like amortization and impairment of acquired intangible assets), costs related to restructuring and cost-saving initiatives (such as severance and facility charges), and certain other items like gains/losses on investments in equity securities and expenses related to legal proceedings.

Does Amgen provide a reconciliation between GAAP and non-GAAP figures?

Yes, the press release furnished with this 8-K filing includes reconciliations that detail how Amgen's non-GAAP financial measures are derived from the most directly comparable GAAP financial measures. Investors are encouraged to review these reconciliations to understand the specific adjustments made.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) has filed an 8-K report on April 30, 2026, to announce its first-quarter 2026 financial results. The filing primarily furnishes the company's earnings press release, which details its unaudited operational results for the quarter ended March 31, 2026, and its financial position as of the same date. Investors should note that the press release includes a significant amount of non-GAAP financial measures, which Amgen uses to provide supplementary information and facilitate a more detailed analysis of its ongoing business operations. The non-GAAP measures include adjusted earnings per share, operating income, operating margin, tax rate, and operating expenses. These adjustments primarily exclude acquisition-related expenses, costs from restructuring and cost-saving initiatives, and other items such as gains/losses on investments and legal proceedings. Amgen asserts that these non-GAAP figures, along with Free Cash Flow (FCF), offer a clearer view of the company's operational performance and liquidity, aiding in comparisons across periods and internal evaluations. Investors are advised to review the reconciliations provided in the press release to understand the differences between GAAP and non-GAAP reporting.

Key Highlights

1Amgen Inc. announced its first-quarter 2026 financial results via an 8-K filing on April 30, 2026.
2The company furnished its earnings press release, detailing Q1 2026 operational results and financial position.
3Amgen is presenting non-GAAP financial measures to offer enhanced insights into its ongoing business performance.
4Key non-GAAP adjustments include acquisition-related expenses, restructuring costs, and certain investment/legal items.
5The company believes non-GAAP measures and Free Cash Flow (FCF) provide useful supplementary information for investors.
6Reconciliations between GAAP and non-GAAP figures are provided within the press release.
7The furnished information is not deemed 'filed' for Section 18 purposes and is not automatically incorporated into other filings.

AMGEN INC 8-K Report, Financial Results (Apr 30, 2026)

Summary

Key Highlights

Frequently Asked Questions